Qiagen N.V. Common Shares (QGEN)
QGEN trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1015820/000101582026000018/0001015820-26-000018-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | QGEN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Netherlands |
| IPO year | 2026 |
| SEC CIK | 0001015820 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | Netherlands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.1B |
| Net income | $424.9M |
| Operating income | $465.9M |
| Net margin | 20.3% |
| Operating margin | 22.3% |
| Revenue growth | +5.7% |
| Cash | $839.0M |
| Total assets | $6.3B |
| P/E (computed) | 24.2× |
| P/S (computed) | 4.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-20 |
| Cash and burn | $839.0M cash; operating cash flow $163.6M a quarter. | Report 2025-12-31 |
| Shares outstanding | 216,920,735 (2025-12-31); 222,290,848 a year earlier; 227,716,433 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE/A filed | 25-NSE/A 2026-01-09 |
| Auditor | EY GmbH & Co. KG Wirtschaftspruefungsgesellschaft, Cologne, Germany | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $2.1B | $424.9M | $654.3M | $839.0M | $1.7B | $2.1B | 20-F 2026-03-20 |
| FY 2024 2024-12-31 | $2.0B | $83.6M | $673.6M | $663.6M | $1.4B | $2.0B | 20-F 2026-03-20 |
| FY 2023 2023-12-31 | $2.0B | $341.3M | $459.5M | $668.1M | $1.5B | $2.0B | 20-F 2026-03-20 |
| FY 2022 2022-12-31 | $2.1B | $423.2M | $715.3M | $730.7M | $1.9B | $2.1B | 20-F 2025-03-31 |
| FY 2021 2021-12-31 | $2.3B | $512.6M | $639.0M | $880.5M | $1.9B | $2.3B | 20-F 2024-03-11 |
| FY 2020 2020-12-31 | $1.9B | $359.2M | $457.8M | $598.0M | $1.9B | $1.9B | 20-F 2023-03-13 |
| FY 2019 2019-12-31 | $1.5B | -$41.5M | $330.8M | $623.6M | $1.7B | $1.5B | 20-F 2022-03-14 |
| FY 2018 2018-12-31 | $1.5B | $190.4M | $359.5M | $1.2B | $2.2B | $1.5B | 20-F 2021-03-05 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FINAL PROSPECTUS SUPPLEMENT | 424B5 | 2009-09-25 |
| Latest annual report | 20-F | 2026-03-20 |
| Latest quarterly / interim | 6-K | 2026-11-06 |
Source: SEC EDGAR submissions feed, 513 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.9% |
| 1 month | +9.8% |
| 3 months | +15.4% |
| Year to date | +10.9% |
| 1 year | +11.7% |
| From 52-week high | -10.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| KRYS | Krystal Biotech Inc. | $297.90 | -2.40% | $8.8B |
| CGON | CG Oncology Inc. | $84.78 | +13.95% | $7.6B |
| TWST | Twist Bioscience Corporation | $105.04 | -5.88% | $7.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier